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The reduction of ketones to enantiopure alcohols is a very important transformation in organic synthesis as it provides valuable building blocks for the flavor, fragrance, fine chemical, and pharmaceutical industries. Precious metals with expensive chiral ligands are generally required for the catalytic hydrogenation of ketones, but these metals are costly and potentially toxic. 2 Thus, there is a current research effort to find highly efficient and enantioselective catalysts based on earth abundant metals for more economical and safer processes without sacrificing activity and selectivity. Recently, iron has received a large amount of attention as a viable catalyst for both asymmetric transfer hydrogenation (ATH) 3 and direct hydrogenation (DH) 4 of polar double bonds. ATH takes place in the presence of a sacrificial reductant as the H + /H -source, as shown in Scheme 1 with isopropanol as the reductant. This transformation will be the focus of this communication.
Scheme 1: General reaction scheme for the ATH of ketones Three iron(II) complexes (1-3 in Figure 1 ) of our iron catalysts for ATH have been synthesized and reported recently. 3m, 4f Complex 1 was found to be highly active in the ATH of ketones with enzyme-like activity. Turnover frequencies (TOF) up to 200 s -1 and enantiomeric excess (ee) up to 90% was observed for the reduction of 3,4-bis(trifluoromethyl)acetophenone (K8). Although complex 1 has unprecedented activity, there is room for improvement with respect to enantioselectivity. Complex 2 has lower activity but provides higher ee (up to 98%) for certain substrates. In some cases there is racemization of the product near the end of the reaction. Complex 3 has higher activity but lower enantioselectivity.
In the preparation of the catalyst, the incorporation of an N-H moiety in the tetradentate ligand required an intensive synthetic approach where first an enantiomerically pure (S,S)-R2PCH2CH2NHCH(Ph)CH(Ph)NH2 ((S,S)-P-NH-NH2) ligand was synthesized and isolated, then it underwent an iron-templated Schiff-base condensation with an -diarylphosphinoacetaldehyde to produce the P-NH-N-P ligand on iron. Complexes 1-3 differ only by the aryl phosphine groups, and complex 3 is so far the only one with unsymmetrical phosphine donors. We propose that the use of a more sterically hindered phosphine such as a dicyclohexylphosphino group on the ligand may improve the enantioselectivity of this system, and this phosphine can be introduced in the final step of the templated ligand synthesis. The present study describes the catalytic reduction of ketones using a new unsymmetrically substituted catalyst 4 which provides alcohols in excellent enantiomeric enrichment without racemization.
The new complex 4 was synthesized using a similar method to that of 1 and 3 as described briefly above.
3m Starting with the air-and moisture-stable dicyclohexylphosphonium dimer and the enantiomerically pure (S,S)-Ph2P-NH-NH2 ligand, the Schiff-base condensation occurred via a metal-mediated template synthesis as shown in Scheme 2. Substitution of the two MeCN with bromide and carbonyl, followed by salt exchange with NaBPh4, afforded complex 4 in moderate yield (40%) as a mixture of two diasteromers. It has been characterized by NMR, ESI-MS, and IR. In the 31 P{ 1 H} NMR spectrum, characteristic doublets at 78.38 ppm and 47.34 ppm, as well as 76.05 ppm and 75.48 ppm correspond to two structural isomers of the complex, the first being the major isomer (75%/25%). Presumably, one isomer would have its C=O syn to the N-H and the other anti. A carbonyl stretch (νCO) was found at 1951 cm -1 , which is typical for such a complex. The catalytic activity of complex 4 was tested for the ATH of ketones K1-K16 and one aldehyde A1, shown in Figure 2 . For all substrates, the (R)-alcohol was produced when using our iron complexes which have enantiopure (S,S)-ligands. The results are summarized in Table 1 . Overall, complex 4 has a lower activity than 1, however the ee of a few substrates have been increased by using the bulky dicyclohexylphosphine. Entries 1-3 show the reduction of acetophenone under different conditions. An ee of 81% was observed when the C/B/S ratio was 1/2/500, but when the catalyst loading was reduced, the ee increased significantly to 93% and 98% with 2 and 8 equivalents of base, respectively. We found that 4 was slightly less active than 1 in the reduction of K1, giving a conversion of 11% lower; however the ee was significantly increased by 20%. In our previous work 3m we found that complex 2 was more enantioselective for the reduction of acetophenone with a 90% ee, but 4 surpasses. Substrates K2 and K4 were reduced with very high ee of 94% and >99%, respectively; however when a more bulky substrate, such as K3 was tested, no conversion was observed. The effective reduction of K4 is noteworthy as Noyori-type catalysts do not hydrogenate it. 5 When the substituents on the phenyl ring were varied as for substrates K5-K8, different effects on catalysis were observed. Complex 4 gave very high conversions of chlorosubstituted ketones K5 and K6, but there were lower conversions of methyl-and CF3-substituted ketones K7 and K8. The ee of the more sterically hindered ortho-and metasubstituted K5 and K8 were higher (94% and 95%, respectively) than the para-substituted ketones K6 and K7. Complex 4 gave a higher ee (95%) for substrate K8 than 1 (90%), however the activity was much lower with only 38% conversion. The resulting alcohol serves as an intermediate in the synthesis of Aprepitant to combat nausea associated with cancer chemotherapy. 6 Complex 4 was found to be imine-functional group tolerant with the high conversion of acetylpyridine (K9) to (R)-α-methyl-2-pyridinemethanol, however catalysis stopped in the presence of the oxygenfunctionalized acetylfuran (K10). Alkylketones K11 and K12 are deactivated to reduction by complex 4 with conversions of 44% and 0%, respectively, as is the bulky cyclohexylphenyl ketone K13. High conversions of benzophenone K14 and acetylnaphthone (K15) were observed, with an ee of 80%, matching complex 1, for the production of (R)-α-methyl-2-naphthalenemethanol. The ATH of the olefinic aryl ketone K16 resulted in a nonselective reduction of both the C=O and C=C bonds with a 40% conversion to reduced products and only a 5% ee of olefin (R)-alcohol. This is different than complex 1 which reduced only the C=O moiety, however with a low yield (55%). Lastly, the hydrogenation of benzaldehyde A17 was very efficient with quantitative conversion in 10 minutes. The products of the reduction of K5, K8, and K9 were isolated via extraction from brine with ether, as well as filtration through a pad of celite. The alcohols 1-(2-chlorophenyl)ethanol and 1-(2-pyridyl)ethanol were isolated without any starting ketone present at 75% and 58% yield, and with 95 and 34% ee, respectively. The reduction of K8 did not go to completion, however, and the alcohol was distilled with a resulting yield of only 30% in 94% ee.
The proposed mechanism of the catalytic reaction is shown in Scheme 3 and is assumed to follow the one that has previously been reported. 3m The precatalyst 4 is activated with 2-8 equivalents of base to form the neutral iron ene-amido species 5a and 5b. It has been found that the proton and hydride of the active catalyst must be on the same side of the ligand plane, and the orientations of the amide and vacant site of 5a do not allow the initial H + /H -transfer to occur in the correct way. However, complex 5b can dehydrogenate iPrOH to give the hydride complex 6. The ketone interacts preferentially in the re configuration with 5b in a 6-membered transition state. The H + /H -transfer then occurs to release the product alcohol and the neutral species 5b, thus closing the catalytic cycle.
Scheme 3: Proposed catalytic cycle for the ATH of ketones
In conclusion, a newly developed unsymmetrical tetradentate P-NH-N-P' ligand has been synthesized on iron. The new precatalyst 4 was tested in the ATH of C=O bonds and gave a TON up to 4300 and ee up to 99%. In comparing the dicyclohexylphosphino-substituted complex 4 with the previously reported diphenylphosphino complex 1 in the ATH of ketones, we find that the enantioselectivity of this system is increased at the expense of catalytic activity. For example, acetophenone, usually a challenging substrate for enantioselective reduction, 1e was hydrogenated with a resulting ee of 98%. The flexible synthesis of our third generation catalysts offers the possibility of tuning their structure for the optimum reduction of a given substrate. This is currently under investigation
Experimental Section
All manipulations were done under inert atmosphere of either nitrogen or argon using P NMR spectra were referenced to 85% H3PO4 (0 ppm). The electrospray ionization mass spectrometry (ESI-MS) data were collected on an AB/Sciex QStar mass spectrometer with an ESI source.
Synthesis of trans-(S,S)-[Fe(Br)(CO)(PPh2CH2CH2NHCHPhCHPhN=C HCH2PCy2)][BPh4] (4):
In the glovebox, sodium methoxide (64 mg, 1.176 mmol) was added to a 100 mL Schlenk flask charged with a stir bar and dicyclohexyl phosphonium bromide (378 mg, 5.88x10 -1 mmol) and 25 mL methanol was added with stirring. This solution was stirred for no more than 2 minutes. A solution of dissolved [Fe(H2O)6][BF4]2 (496 mg, 1.47 mmol) in 20 mL acetonitrile was added to the Schlenk flask, followed by a solution of (S,S)-PPh2CH2CH2NHCH(Ph)CH(Ph)NH2 in 10 mL methanol. This resulted in a purple solution. This was left to stir at room temperature for 16 h, after which a colour change from purple to pink was observed. The solvent was removed in vacuo. KBr (140 mg, 4.70 mmol) was added to the flask which was sealed and removed from the glovebox. The flask was purged and placed under CO atmosphere using Schlenk techniques. 20 mL acetone in a syringe was removed from the glovebox and injected into the flask with stirring for 1.5 hours. The solvent was removed under vacuum and the residual orange solid was redissolved in 20 mL acetone while under CO atmosphere. This was stirred for 1 hour, after which the solvent was removed and the flask brought into the glovebox, where the remaining steps occurred. The solid residue was dissolved in 20 mL dichloromethane and filtered through a pad of celite, then through a 25 mm Syringe Filter PTFE membrane (pore size 0.45 µm). The clear orange solution was dried in vacuo, then redissolved in minimal methanol. This solution was added to a vial charged with a stir bar and NaBPh4 (402 mg, 1.294 mmol) dissolved in minimal methanol, from which a yellow solid precipitated. This solid was filtered off and washed with diethyl ether (3x15 mL) and dried overnight. If the purity by NMR was not sufficient, the solid was redissolved in minimal dichloromethane and precipitated out by addition of diethyl ether. (10 mg, 8.9x10 -3 mmol) . The substrate (4.43x10 mmol) was added and the mixture was stirred. If the substrate is a liquid, the mixture was stirred until complex 4 was completely dissolved. 3.61 g iPrOH was added and the solution was stirred for 5 minutes. A stock solution of KOtBu (20 mg, 0.18 mmol) in 0.98 g iPrOH was stirred until all the base was dissolved. 0.1 g or 0.4 g stock solution (2 and 8 eq., respectively) was diluted by 1.0 g or 0.7 g iPrOH, respectively and added to the 20-mL vial to activate the precatalyst and start catalysis. 0.1 mL samples were taken via syringe and injected into teflon-sealed GC vials prepared with wet, aerated iPrOH to quench catalysis.
General procedure for ATH: Table 1 entries 2-3:
The quantity of the precatalyst was measured via a stock solution method. A concentrated stock solution was made by dissolving complex 4 (22 mg, 1.97x10 -2 mmol) in 6.08 g cold dichloromethane. After all the solid was dissolved, the solution was immediately sucked into a syringe. The solution was then divided into equal portions into several 20 mL vials such that each portion has 0.2 g of the stock solution, and then dichloromethane was removed in vacuo. These operations led to a precatalyst quantity of 6.48x10 -4 mmol in each vial. The base was prepared by dissolving KOtBu (10 mg, 0.089 mmol) in iPrOH (1.02 g, 1.30 mL). iPrOH (6.63 g, 8. 44 mL), substrate (3.95 mmol) and a clean stirring bar were added to the vial that contains the precatalyst and the solution was stirred for 5 minutes, or until all the precatalyst was dissolved. 0.015 g or 0.06 g of the base stock solution (2 or 8 eq. base) was added into a vial that contains 0.546 g or 0.501 g of iPrOH, respectively, and the mixed solution was then added into the catalyst solution to start the catalytic reaction. 0.1 mL samples were taken via syringe and injected into teflon-sealed GC vials prepared with wet, aerated iPrOH to quench catalysis.
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Supporting Table 1 OH erature 60 °C (S)-isomer = 9 S12 9.92; starting material = 3.74. 
